about
Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccinesBuilding collaborative networks for HIV/AIDS vaccine development: the AVIP experience.HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.T-tropic human immunodeficiency virus (HIV) type 1 Nef protein enters human monocyte-macrophages and induces resistance to HIV replication: a possible mechanism of HIV T-tropic emergence in AIDS.HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodiesDo not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV.Effect of MHC haplotype on immune response upon experimental SHIVSF162P4cy infection of Mauritian cynomolgus macaquesAntibody protection: passive immunization of neonates against oral AIDS virus challenge.Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.Problems and emerging approaches in HIV/AIDS vaccine development.Older rhesus macaque infants are more susceptible to oral infection with simian-human immunodeficiency virus 89.6P than neonates.Trans-dissemination of exosomes from HIV-1-infected cells fosters both HIV-1 trans-infection in resting CD4(+) T lymphocytes and reactivation of the HIV-1 reservoir.Influence of MHC class I and II haplotypes on the experimental infection of Mauritian cynomolgus macaques with SHIVSF162P4cy.cis expression of the F12 human immunodeficiency virus (HIV) Nef allele transforms the highly productive NL4-3 HIV type 1 to a replication-defective strain: involvement of both Env gp41 and CD4 intracytoplasmic tails.Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation.E2F activates late-G1 events but cannot replace E1A in inducing S phase in terminally differentiated skeletal muscle cells.Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells.AN EXOSOME-BASED VACCINE PLATFORM IMPARTS CYTOTOXIC T LYMPHOCYTE IMMUNITY AGAINST VIRAL ANTIGENS.Genetic diversity in the env V1-V2 region of proviral quasispecies from long-term controller MHC-typed cynomolgus macaques infected with SHIVSF162P4cyTime dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaquesVaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant ΔV2 EnvAnti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered ExosomesTerminally differentiated skeletal myotubes are not confined to G0 but can enter G1 upon growth factor stimulationPost-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaquesExosomes in Therapy: Engineering, Pharmacokinetics and Future ApplicationsDNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and TumorsThe Intracellular Delivery Of Anti-HPV16 E7 scFvs Through Engineered Extracellular Vesicles Inhibits The Proliferation Of HPV-Infected CellsTumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs
P50
Q27333734-5277A830-E8F2-45B4-B5D3-A2C4D816383AQ30356937-FF601E6A-A560-4592-8CD7-A883C7E57BD4Q30381447-617E6DD1-B6E4-40D0-987F-8EC82274145CQ31830559-AFFC4BC1-97FB-4EFD-A9C1-AC0F31833968Q34477471-1D7AF700-14EB-463C-ACFC-C18967EF614BQ35023530-A91D6C0F-B2FC-46DA-86D8-3C1412959863Q35138516-5EDDA7CD-6E03-4B03-B98D-630A79335F4EQ35172885-F518F392-B53C-4612-9168-75609C1E0047Q35628408-2A9EB5F9-3AEE-4588-84DC-00F01E9E02DCQ36109585-3BA1EC3D-B730-463D-A905-0F90F6C94E55Q36758574-0030152D-4995-46F7-972D-CB5F57A15C5AQ37742900-C7AEA5C9-7673-45D0-A940-5E1AD6F380C6Q38802980-4CB76A5A-9281-47B4-AD27-6FAEFCA7B893Q38915579-DD724E89-A5F2-48AA-BA0F-3F7EEB2FCD54Q39588750-6C109C71-7CFC-40FB-8E85-FBD5439C079BQ40140715-B575D943-4513-4973-94D1-EFD08EBAA50AQ40928313-D75DA26D-8AE6-4E72-8919-FC779A24A15AQ44160155-96E88A2C-AAEA-406D-AC0F-07F0465FE869Q44280840-72763C04-CBE6-479B-A326-460722636215Q47215348-17DC5F81-0603-4962-B452-83189103E80BQ47222531-D3E53FA0-7640-47B3-BEB1-E2AF8CBE13CFQ57471517-7EB68D66-8B6A-4832-B574-AFF4FEF197D4Q57697548-EA575F6B-F24E-46FE-BD3C-082FCCDDAEA4Q61641087-BA009942-EAC2-4416-9537-88A822D0E76AQ64244575-6191675D-719E-4723-8F21-C0BDCC206BB2Q64382771-22B13940-D1D0-4F5D-85A2-68EFA64AB3B5Q78853255-B5FCCBAE-A44F-4B98-94ED-0749A96C3122Q88739958-15D9A16E-3616-4485-9F2E-352E52B7CF7EQ91244092-A84BB003-C196-4F16-B705-FC980AE7277FQ91737281-51C8CFC7-6CB0-4EB1-8E46-445C0E907D10Q92505851-E1FE261F-EA61-4031-91CD-11D51AEBB82A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Flavia Ferrantelli
@ast
Flavia Ferrantelli
@en
Flavia Ferrantelli
@es
Flavia Ferrantelli
@nl
Flavia Ferrantelli
@sl
type
label
Flavia Ferrantelli
@ast
Flavia Ferrantelli
@en
Flavia Ferrantelli
@es
Flavia Ferrantelli
@nl
Flavia Ferrantelli
@sl
prefLabel
Flavia Ferrantelli
@ast
Flavia Ferrantelli
@en
Flavia Ferrantelli
@es
Flavia Ferrantelli
@nl
Flavia Ferrantelli
@sl
P106
P31
P496
0000-0002-0768-1078